Results of the European Group for the Study of Resistant Depression (GSRD)—basis for further research and clinical practice

L Bartova, M Dold, A Kautzky, C Fabbri… - The World Journal of …, 2019 - Taylor & Francis
Objectives: The overview outlines two decades of research from the European Group for the
Study of Resistant Depression (GSRD) that fundamentally impacted evidence-based …

Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies

JD Rosenblat, Y Lee, RS McIntyre - The Journal of clinical …, 2017 - psychiatrist.com
Objective: Pharmacogenomic testing has become scalable and available to the general
public. Pharmacogenomics has shown promise for predicting antidepressant response and …

The promise of machine learning in predicting treatment outcomes in psychiatry

AM Chekroud, J Bondar, J Delgadillo… - World …, 2021 - Wiley Online Library
For many years, psychiatrists have tried to understand factors involved in response to
medications or psychotherapies, in order to personalize their treatment choices. There is …

Is AI the future of mental healthcare?

F Minerva, A Giubilini - Topoi, 2023 - Springer
Over the past decade, AI has been used to aid or even replace humans in many
professional fields. There are now robots delivering groceries or working in assembling lines …

An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline

R Uher, KE Tansey, T Dew, W Maier… - American Journal of …, 2014 - Am Psychiatric Assoc
Objective: Major depressive disorder has been linked with inflammatory processes, but it is
unclear whether individual differences in levels of inflammatory biomarkers could help …

Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials

CA Bousman, K Arandjelovic, SG Mancuso… - …, 2019 - Taylor & Francis
Aim: To conducted a systematic review and meta-analysis of prospective, randomized
controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools …

Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial

V Pérez, A Salavert, J Espadaler, M Tuson, J Saiz-Ruiz… - BMC psychiatry, 2017 - Springer
Abstract Background A 12-week, double-blind, parallel, multi-center randomized controlled
trial in 316 adult patients with major depressive disorder (MDD) was conducted to evaluate …

[HTML][HTML] Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical …

P Bradley, M Shiekh, V Mehra, K Vrbicky… - Journal of psychiatric …, 2018 - Elsevier
The objective of this study was to evaluate the effect of pharmacogenetics-guided treatment
on patients diagnosed with depression and/or anxiety, in a diverse set of clinical settings, as …

Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data

D Taliaz, A Spinrad, R Barzilay, Z Barnett-Itzhaki… - Translational …, 2021 - nature.com
Major depressive disorder (MDD) is complex and multifactorial, posing a major challenge of
tailoring the optimal medication for each patient. Current practice for MDD treatment mainly …

Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing

Z Zeier, LL Carpenter, NH Kalin… - American Journal of …, 2018 - Am Psychiatric Assoc
The accrual and analysis of genomic sequencing data have identified specific genetic
variants that are associated with major depressive disorder. Moreover, substantial …